Bristol-Myers Squibb Co. v. Copley Pharmaceutical, Inc.

How courts have described this case

Verbatim parenthetical descriptions written by other courts when citing this decision. Ranked by citation-network relevance.

• dismissing antitrust counterclaim without prejudice because “[without tentative FDA approval, [counterclaim plaintiff] could not now enter the market, regardless of the pending [patent] litigation”
• dismissing an antitrust counterclaim of second ANDA filer against pioneer drug company because the counterclaimant failed to show antitrust injury where the statutory scheme, and not the pioneer drug company, prevented it from entering the market
• finding no standing without tentative FDA approval

Source: CourtListener parenthetical corpus (CC0).